Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

2.

Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.

Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N.

J Interferon Cytokine Res. 2017 Jun;37(6):278-286. doi: 10.1089/jir.2016.0078. Epub 2017 Apr 25.

PMID:
28440692
3.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

4.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
5.

Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.

Akkarathamrongsin S, Payungporn S, Thong VD, Poovorawan K, Prapunwattana P, Poovorawan Y, Tangkijvanich P.

World J Gastroenterol. 2014 Aug 14;20(30):10599-605. doi: 10.3748/wjg.v20.i30.10599.

6.

Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.

Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM.

AIDS. 2013 Mar 13;27(5):687-96. doi: 10.1097/QAD.0b013e32835ce2c1.

PMID:
23196939
7.

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.

AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.

8.

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):95-9. doi: 10.1097/QAI.0b013e3182020596.

9.

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.

Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N.

Hepatology. 2012 Jan;55(1):20-9. doi: 10.1002/hep.24623. Epub 2011 Nov 29.

PMID:
21898478
10.

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.

Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

PMID:
21374656
11.

IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.

Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A.

World J Gastroenterol. 2014 Sep 28;20(36):13146-52. doi: 10.3748/wjg.v20.i36.13146.

12.

Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.

Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P.

PLoS One. 2015 Sep 4;10(9):e0137365. doi: 10.1371/journal.pone.0137365. eCollection 2015.

13.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.

Gut. 2013 Sep;62(9):1340-6. doi: 10.1136/gutjnl-2012-302553. Epub 2012 Nov 7.

14.

Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.

Grandi T, da Silva CM, Amaral KM, Picon PD, Costi C, da Fré NN, Fiegenbaum M, Niel C, Rossetti ML.

Mem Inst Oswaldo Cruz. 2013 Feb;108(1):48-53.

15.

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.

Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, Haagmans B, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottilil S.

J Med Virol. 2014 Feb;86(2):177-85. doi: 10.1002/jmv.23773. Epub 2013 Oct 26.

PMID:
24166150
16.

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

J Hepatol. 2011 Aug;55(2):322-7. doi: 10.1016/j.jhep.2010.10.037. Epub 2010 Dec 13.

PMID:
21147186
17.

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG.

Gastroenterology. 2010 Jun;138(7):2307-14. doi: 10.1053/j.gastro.2010.02.009. Epub 2010 Feb 19.

18.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
19.

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.

J Viral Hepat. 2011 Jul;18(7):e325-31. doi: 10.1111/j.1365-2893.2010.01425.x. Epub 2011 Jan 13.

PMID:
21692944
20.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

Supplemental Content

Support Center